BN Business News
Add your company to Business Communicator →

Business · 20/12/2004

NIH to Grant Exclusive License for Cocaine Therapeutics

The National Institutes of Health is considering granting an exclusive license to Phase2 Discovery for its cocaine therapeutics technology, which may be limited to treating Attention Deficit Hyperactivity Disorder (ADHD).

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights